'Mtx' diaporamas de présentation

2.09k views • 173 slides

Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate

New Evidence reports on presentations given at EULAR 2009. Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate. Report on EULAR 2009 presentations.

680 views • 51 slides

609 views • 46 slides

?? RA ??????

?? RA ??????. ?????????? ???. 84. Lancet. 2012; 378: 1712-1720. (Swefot trial) 85. Ann Rheum Dis. 2013; 72: 72-78. (tREACH trial) 86. Arthritis Rheum. 2012; 64: 2824-2835. (TEAR) 87. Ann Rheum Dis. 2013; 72: 851-857. (NEO-RACo ?? ) 88. N Engl J Med. 2013; 369: 307-318.

601 views • 42 slides

INCIDENCE OF DELAYS IN CHEMOTHERAPY DUE TO METHOTREXATE TOXICITY IN TREATMENT OF OSTEOSARCOMA

INCIDENCE OF DELAYS IN CHEMOTHERAPY DUE TO METHOTREXATE TOXICITY IN TREATMENT OF OSTEOSARCOMA. M. Perisoglou, B. Seddon, S. Daniels, N. Mayne, J. Whelan Department of Oncology University College Hospital, London, UK. HIGH-DOSE METHOTREXATE IN TREATMENT OF OSTEOSARCOMA.

549 views • 38 slides

IL-6R inhibition: A new CHARISMAtic approach to RA therapy

425 views • 34 slides

Neurology Case Presentation

Neurology Case Presentation. Rawan Albadareen, MD PGY-3 5/17/2013. Clinical presentation. A 58 YO female with pre-B cell acute lymphoblastic leukemia (Philadelphia chromosome positive) w CNS involvement. She was undergoing CTX high dose MTX- Ara -C .

447 views • 24 slides

ALL-REZ BFM Study for Treatment of Children with ALL - Relapse

ALL-REZ BFM Study for Treatment of Children with ALL - Relapse. 25% of children with ALL suffer relapses Multi-centre study to optimise risk adapted treatment About 100 participating centres Since 1983 more than 2000 relapses registered

451 views • 21 slides

Delayed Neurotoxicity

Delayed Neurotoxicity. The cumulative risk at 5 years to develop overt dementia is 24-30% (1,2). For patients aged > 60 year the risk of dementia at 7 years is 58% (2). Multivariate analysis shows that only radiotherapy is a significant factor related to neurotoxicity (1).

330 views • 17 slides

Group Meeting 2004/07/08

227 views • 12 slides

BeSt Study: Patient Characteristics

234 views • 7 slides